Regulus Therapeutics Inc.
RGLS
Rang în acțiuni
#17328
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Preț acțiune
$8.16
Ultima sincronizare: 2025-06-26
Capitalizare de piață
$234.57M
Schimbare (1 zi)
0.00%
Schimbare (1 an)
-88.86%
Țară
US
Tranzacționează Regulus Therapeutics Inc. (RGLS)
Categorie
Healthcare
Istoricul spliturilor pentru Regulus Therapeutics Inc. (RGLS)
Acțiunea Regulus Therapeutics Inc. (simbol: RGLS) a trecut printr-un total de 0 splituri.
Cel mai recent split a avut loc pe Oct 20, 2026.
O acțiune RGLS cumpărată înainte de Oct 20, 2026 este echivalentă astăzi cu 0 acțiuni RGLS.
Cel mai recent split a avut loc pe Oct 20, 2026.
O acțiune RGLS cumpărată înainte de Oct 20, 2026 este echivalentă astăzi cu 0 acțiuni RGLS.
Listă splituri acțiuni
| An | Split | Multiplu | Multiplu cumulativ |
|---|---|---|---|
| Nu sunt suficiente date pentru perioada selectată. | |||
Splituri pentru companii similare sau competitori
| Companie | Număr total de splituri | Multiplu cumulativ | Țara |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
